Clinical trials: Bacteriophage Therapy
Cystic Fibrosis, Nontuberculous Mycobacterial Lung Disease
Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria
About 10 people with cystic fibrosis (CF) and persistent Nontuberculosis mycobacteria (NTM) infection despite treatment will be screened to find out if their NTM infection has at least one mycobacteriophage that is effective in…
- Conditions
- Cystic Fibrosis, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection, Mycobacterium Infections
- Trial name
- POSTSTAMP (NCT06262282)
- Testing
- mycobacteriophage
- Where
- 18 sites in United States
- Volunteers
- 10 people
- Sponsor
- National Jewish Health
Urinary Tract Infections, Transplant-Related Disorder
Treatment Chronic UTI Post Kidney Transplant
Urinary tract infections (UTIs) with extended-spectrum -lactamase (ESBL)-positive Enterobacteriums (ESBL-E) are a common infectious complication of renal transplant recipients, with 10% of patients suffering from UTIs with ESBL-E…
- Trial name
- NCT05967130
- Testing
- Phage
- Where
- Iran
- Volunteers
- 5 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Prosthetic Joint Infections of Hip, Staphylococcus Aureus Infection
Bacteriophage Therapy for Methicillin-Sensitive Staphylococcus Aureus Prosthetic Joint Infection
This is a single-patient, phase I/II clinical trial that aims to evaluate the potential of a bacteriophage cocktail to treat and prevent the recurrence of a methicillin-susceptible Staphylococcus aureus prosthetic joint infection…
- Trial name
- PHAGE-2024-01 (NCT06456424)
- Testing
- Phage therapy
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- University of Calgary
Prosthetic Joint Infections of Hip, Bacteriophage Therapy
Bacteriophage Therapy for Staphylococcus Lugdunensis Prosthetic Joint Infection
This is a single-patient, phase I/II clinical trial that aims to evaluate the potential of a bacteriophage drug product to treat and prevent the recurrence of a Staphylococcus lugdunensis prosthetic joint infection of the hip.
- Trial name
- NCT07461337
- Testing
- Five phage anti-Staphylococcus aureus bacteriophage cocktail
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- University of Calgary
Severe Infection
PHAGEinLYON Clinic Cohort Study: a Descriptive Study of Severe Infections Treated With Phage Therapy at the HCL.
PHAGEinLYON Clinic cohort study is a single site non-interventional retrospective and prospective study, initiated by the Hospices Civils de Lyon.
- Trial name
- NCT06185920
- Testing
- Description of severe infection
- Where
- France
- Volunteers
- 250 people
- Sponsor
- Hospices Civils de Lyon
Individual Patient Expanded Access for AB-SA01, an Investigational Anti-Staphylococcus Aureus Bacteriophage Therapeutic
The purpose of the expanded access program is to allow physicians to provide treatment with investigational drug, AB-SA01, for patients with serious or immediately life-threatening Staphylococcus aureus infections, for which no…
- Trial name
- NCT03395769
- Testing
- AB-SA01
- Sponsor
- Armata Pharmaceuticals, Inc.
Individual Patient Expanded Access for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage Therapeutic
The purpose of the expanded access program is to allow physicians to provide treatment with investigational drug, AB-PA01, for patients with serious or immediately life-threatening Pseudomonas aeruginosa infections, for which no…
- Trial name
- NCT03395743
- Testing
- AB-PA01
- Sponsor
- Armata Pharmaceuticals, Inc.
Acute Tonsillitis
Bacteriophage Therapy in Tonsillitis
The patients received bacteriophage therapy with a liquid piobacteriophage complex (liquid pyobacteriophage complex - PCL). PСL was administered via nebulizer inhalation to irrigate the tonsil mucosa.
- Trial name
- NCT04682964
- Testing
- Nebulizer inhalation irrigation of the mucous membranes of the tonsils with a bacteriophage.
- Where
- Uzbekistan
- Volunteers
- 128 people
- Sponsor
- Tashkent State Medical University (Tashkent Pediatric Medical Institute), Uzbekistan
Bacterial Infections
Bacteriophage Therapy of Difficult-to-treat Infections
A retrospective, observational analysis of the first one hundred consecutive cases of bacteriophage therapy of difficult-to-treat infections, facilitated by a Belgian consortium.
- Trial name
- BT100 (NCT05498363)
- Testing
- Bacteriophage therapy
- Volunteers
- 100 people
- Sponsor
- Queen Astrid Military Hospital
Prosthetic Joint Infections of Hip
Bacteriophage Therapy for Morganella Morganii Prosthetic Joint Infection
This is a single-patient, phase I/II clinical trial that aims to evaluate the potential of a bacteriophage drug product to treat and prevent the recurrence of a Morganella morganii prosthetic joint infection of the hip.
- Trial name
- PHAGE-MOM-001 (NCT06814756)
- Testing
- phage therapy
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- University of Calgary
Musculoskeletal Infection, Chronic Rhinosinusitis (Diagnosis)
Establishing Personalized Phage Therapy and Its Comparative Cost in Difficult-to-treat Infections (EPHICACI)
EPHICACI is a multicenter, prospective study that continues and expands the monocentric PHAGEFORCE registry initiated at UZ Leuven.
- Conditions
- Musculoskeletal Infection, Chronic Rhinosinusitis (Diagnosis), Persistent Bacteremia, Pulmonary Infection
- Trial name
- EPHICACI (NCT06368388)
- Testing
- Prospective data collection phage therapy, Prospective data collection standard-of-care
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Non-Tuberculous Mycobacterial (NTM) Pneumonia, Mycobacterium Abscessus Infection
Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection
This study aims to use mycobacteriophage therapy, using identified in-vitro effective Mycobacteriophage Muddy_HRMN0052, along with combination conventional antimycobacterial therapy for their NTM pulmonary disease with…
- Trial name
- NCT07228702
- Testing
- Mycobacteriophage Muddy_HRMN0052, Amikacin Injection, Clofazimine
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- Vancouver Coastal Health
Diarrhea
Antibacterial Treatment Against Diarrhea in Oral Rehydration Solution
This study hopes to demonstrate the potentials of a new form of therapy for childhood diarrhea, a major cause of morbidity and deaths in Bangladesh and other developing countries, and thus a priority for improving child health.
- Trial name
- NCT00937274
- Testing
- T4 phage cocktail test, Commercial T4 phage cocktail, standard oral rehydration solution (ORS)
- Where
- Bangladesh
- Volunteers
- 120 people
- Sponsor
- Société des Produits Nestlé (SPN)